Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of RNAi therapeutics on cardiac parameters in patients with hereditary transthyretin amyloidosis initially treated with stabilizers: A French real-world study.

Archives of cardiovascular diseases - 1 Jan 2026

Fraix Antoine, Algalarrondo Vincent, Lairez Olivier, Arnal Marie, Piriou Nicolas, Michaud Maud, Habib Gilbert, Roubille François, Lucas Claire, Duval Antoine Jobbé, Bachelet Bérengère, Donal Erwan, Damy Thibaud, Réant Patricia, Kharoubi Mounira, Huttin Olivier

Abstract excerpt

BACKGROUND: Cardiomyopathy in hereditary transthyretin amyloidosis (ATTRv) is increasingly reported due to improved diagnostic techniques and increased clinician awareness. Optimal therapeutic strategies for mixed phenotypes remain challenging. AIMS: To describe the changes in cardiac parameters among patients with ATTRv and cardiac involvement who had switched from stabilizer monotherapy to ribonucleic acid...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amyloid Neuropathies, Familial
Share to Cardiomyopathies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Progression

Share to Drug Substitution

Share to France

Share to RNA, Small Interfering

Share to Treatment Outcome

Share to Ventricular Function, Left

Source

Identifiers

PMID: 41724605
DOI: 10.1016/j.acvd.2025.11.014

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of RNAi therapeutics on cardiac parameters in patients with hereditary transthyretin amyloidosis initially treated with stabilizers: A French real-world study.PMID 41724605Read ↗

Treatment characteristics of patients with hereditary transthyretin amyloidosis: a cohort studySemantic proximity Read ↗

Treatment characteristics of patients with hereditary transthyretin amyloidosis: a cohort studySemantic proximity Read ↗

Transthyretin Amyloid Cardiomyopathy–2025 Update: Current Diagnostic Approaches and Emerging Therapeutic OptionsSemantic proximity Read ↗

A Review of Novel Agents and Clinical Considerations in Patients With ATTR Cardiac Amyloidosis.Semantic proximity Read ↗

Transthyretin Amyloid Cardiomyopathy Treatment: An Updated ReviewSemantic proximity Read ↗

From stabilization to silencing in transthyretin amyloid cardiomyopathy: why sequencing should be treat-to-trajectory, not 'one-and-done'.Semantic proximity Read ↗

Emerging Pharmacological Strategies for Cardiac Amyloidosis: A Qualitative Analysis of Interventional Clinical Trials Registered on ClinicalTrials.govSemantic proximity Read ↗

Real-life experience with inotersen in hereditary transthyretin amyloidosis with late-onset phenotype: Data from an early-access program in Italy.Semantic proximity Read ↗

Emerging, novel gene-modulating therapies for transthyretin amyloid cardiomyopathySemantic proximity Read ↗

Multicenter study of patients with transthyretin cardiac amyloidosis in Poland: Clinical characteristics, genotyping, electrocardiographic features, outcome predictors, and tafamidis treatment outcomes.Semantic proximity Read ↗

Clinical Practice and Diagnostic Trends in Hereditary Transthyretin Amyloidosis: A 25-Year Observational Study.Semantic proximity Read ↗

Treating amyloid transthyretin cardiomyopathy: lessons learned from clinical trialsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.